Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response

Journal of Immunotherapy

Volumn 22, Issue 4, 1999, Pages 288-298

  Dudley, Mark E ^a   Nishimura, Michael I ^a   Holt, Agnieszka K C ^b   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Cytotoxic T lymphocyte; Gp100; Immunotherapy; Melanoma; T cell receptor

Indexed keywords

EPITOPE; FREUND ADJUVANT; G9 209 2M; GAMMA INTERFERON; HLA A2 ANTIGEN; MELANOMA ANTIGEN; RECOMBINANT INTERLEUKIN 12; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; MONONUCLEAR CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL LINE;

EID: 0032993029     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199907000-00002     Document Type: Article

References (25)

1. Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gplOO and their use for immuno-gene therapy. Intern Rev Immunol 1997;14:173-92.
2. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
3. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy [published erratum appears in Cancer Res 1994;54:3952]. Cancer Res 1994;54:3124-6.
4. Robbins PF, el-Gamil M, Li YF, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
5. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
6. van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
7. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TOP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-16.
8. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-40.
9. Brichard V, van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
10. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
11. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
12. Marineóla FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gplOO in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996;19:192-205.
13. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
14. Tsai V, Southwood S, Sidney J, et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. ] Immunol 1997;158:1796-802.
15. Salgaller ML, Afshar A, Marineóla FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gplOO by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
16. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
17. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19:81-4.
18. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gplOO modified at HLA-A*0201 -binding residues. J Immunol 1996;157:2539-48.
19. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
20. Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
21. Salter RD, Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J 1986;5:943-9.
22. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor [see comments]. N Engl J Med 1995;333:1038-44.
23. Ferradini L, Roman-Roman S, Azocar J, Michalaki H, Triebel F, Hercend T. Studies on the human T cell receptor alpha/beta variable region genes. II. Identification of four additional V beta subfamilies. Eur J Immunol 1991;21:935-42.
24. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996;93:4102-7.
25. Cole DJ, Weil DP, Shamamian P, et al. Identification of MART- 1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope [published erratum appears in Cancer Res 1994;54:6014], Cancer Res 1994;54:5265-8.